Special Issue

Advances in the Treatment of Schizophrenia

Message from the Guest Editors

Schizophrenia remains one of the most serious clinical conditions. It is associated with a chronic relapsing course and pronounced cognitive dysfunction in a large proportion of patients, despite therapeutic advancements over the past few decades. This Special Issue will provide a review of recent and historial research in the field of schizophrenia pharmacology and therapeutics. Furthermore, this issue will consider the mechanisms underlying schizophrenia development and progression, symptomatic improvement, improving adherence to pharmacologic treatment and the treatment of side effects to allow personalized care.

Guest Editors

Prof. Dr. Adam M. Kaye

Department of Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific, Stockton, CA 95207, USA

Dr. Amber Edinoff

Department of Psychiatry and Behavioral Medicine, LSU Health Shreveport, Shreveport, LA 71103, USA

Deadline for manuscript submissions

closed (28 February 2022)

MDPI

Neurology International

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.8
Indexed in PubMed

About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Junji Yamauchi
1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
2. Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Clinical Neurology)